F-group (family)
2003.1.5.46 MTS
Ligands and drugs
658
Member domains
65
with ligand contacts (≤ 4 Å)
9.9% of members
48
with DrugDomain annotations
7.3% of members
45
with a DrugBank compound
6.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2003.1.5.46 belongs to X-group 2003 Rossmann-like, which binds 8.9 ligand superclasses per 20 proteins, broader than 78% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB01752 | SAH | S-adenosyl-L-homocysteine | 25 |
| DB00118 | SAM | Ademetionine | 19 |
| DB00130 | GLN | L-Glutamine | 3 |
| DB03473 | MEQ | N5-Methylglutamine | 3 |
| DB02857 | GMP | Guanosine | 1 |
| DB04263 | GET | Geneticin | 1 |
| DB13673 | 9CS | Bekanamycin | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| SAH | S-ADENOSYL-L-HOMOCYSTEINE | 29 |
| SAM | S-ADENOSYLMETHIONINE | 20 |
| CAmetal | CALCIUM ION | 5 |
| MGmetal | MAGNESIUM ION | 4 |
| GLN | GLUTAMINE | 3 |
| MEQ | N5-METHYLGLUTAMINE | 3 |
| 7QM | (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-3-(methylamino)-alpha-D-glucopyranosyl]oxy}-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside | 2 |
| PG0 | 2-(2-METHOXYETHOXY)ETHANOL | 2 |
| QVR | (2~{R},3~{R},4~{S},5~{R})-2-(6-aminopurin-9-yl)-5-[(~{E})-prop-1-enyl]oxolane-3,4-diol | 2 |
| 62X | 5'-{[(3S)-3-amino-3-carboxypropyl][3-(dimethylamino)propyl]amino}-5'-deoxyadenosine | 1 |
| 6D6 | 5'-{[(3S)-3-amino-3-carboxypropyl](3-aminopropyl)amino}-5'-deoxyadenosine | 1 |
| 6LC | 9-[(5E)-7-carbamimidamido-5,6,7-trideoxy-beta-D-ribo-hept-5-enofuranosyl]-9H-purin-6-amine | 1 |
| 7XP | (1R,2S,3S,4R,6S)-4,6-diamino-3-[(3-amino-3-deoxy-alpha-D-xylopyranosyl)oxy]-2-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside | 1 |
| 827 | (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside | 1 |
| 9CS | (1R,2S,3S,4R,6S)-4,6-DIAMINO-3-[(3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL)OXY]-2-HYDROXYCYCLOHEXYL 2,6-DIAMINO-2,6-DIDEOXY-ALPHA-D-GLUCOPYRANOSIDE | 1 |
| A1CBE | N-(4-{[(3aS,4R,6S,6aR)-6-(3-chlorophenyl)-2-propanoyloctahydrocyclopenta[c]pyrrol-4-yl]oxy}phenyl)acetamide | 1 |
| A1IC3 | (2~{S})-4-[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl-[(3~{S})-3-azanyl-4-oxidanyl-4-oxidanylidene-butyl]amino]-2-azanyl-butanoic acid | 1 |
| A1IC5 | (2~{S})-4-[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl-[(3~{S})-3-azanylhexyl]amino]-2-azanyl-butanoic acid | 1 |
| A1IC6 | (2~{S})-4-[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl-[3-(2-phenylethylamino)propyl]amino]-2-azanyl-butanoic acid | 1 |
| A1IC7 | (2~{S})-4-[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl-[(3~{S})-3-azanyl-3-phenyl-propyl]amino]-2-azanyl-butanoic acid | 1 |